Current status of indoleamine-2, 3-dioxygenase-1 in tumor immunity and treatment
10.3760/cma.j.cn115355-20200323-00133
- VernacularTitle:吲哚胺-2, 3-双加氧酶-1在肿瘤免疫及治疗中的研究现状
- Author:
Shiwen MEI
1
;
Zheng LIU
;
Qian LIU
Author Information
1. 国家癌症中心 中国医学科学院肿瘤医院结直肠外科，北京 100020
- From:
Cancer Research and Clinic
2020;32(9):597-600
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors have achieved some efficacies in immunotherapy, but they are still limited in improving long-term survival. The effectiveness of tumor immunotherapy on the one hand depends on the efficient recognition of tumors and specific immunity by the positive acting autoimmune system, on the other hand it depends on the negative acting tumor immune escape. Indoleamine-pyrrole 2,3-dioxygenase-1 (IDO1) as an important rate-limiting enzyme in the metabolic pathway of tryptophan, has attracted scholars' attention. And it has been found that its high expression can develop an immune escape and inhibition, and the research of IDO1 in tumor immunity is expected to provide new targets and approaches for immunotherapy. The paper reviews the current research status and progress of IDO1 in malignant tumors.
